Anuja Kriplani
Papers
1
Total Citations
57
H-Index
1
About
Dr. Anuja Kriplani is a leading voice in the evolving landscape of head and neck oncology, with a focused expertise in treatment deintensification for human papillomavirus (HPV)-associated oropharyngeal cancer. Her major contribution lies in navigating the critical balance between reducing long-term treatment toxicities and maintaining excellent oncologic outcomes for this rising patient population. Her most cited work, the 2022 consensus paper on "Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus‐associated oropharyngeal cancer" (57 citations), synthesizes the field's most pressing debates, offering a roadmap for clinical trials and practice. This work underscores her impact in shaping how clinicians approach the favorable prognosis of HPV-positive disease, moving away from the morbidities of traditional chemoradiation. Dr. Kriplani’s research is instrumental for students and researchers seeking to understand the paradigm shift toward personalized, less aggressive therapies, and her consensus-building efforts have made her a key figure in defining the next generation of treatment standards for this common cancer.
Research Focus
Key Achievements
Top Papers
- 1